Reply
The changes of BCVA were 0.10 ± 0.37 in polypoidal CNV and 0.13 ± 0.18 in idiopathic PCV, with no significant difference between the 2 groups (P = .740). [...]in our study, there were no significant differences between polypoidal CNV and idiopathic PCV in both anti-vascular endothelial growth factor...
Gespeichert in:
| Veröffentlicht in: | American journal of ophthalmology 2017-02, Vol.174, p.182 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 182 |
| container_title | American journal of ophthalmology |
| container_volume | 174 |
| creator | Maruyama-Inoue, Maiko Yamane, Shin Sato, Shimpei Kadonosono, Kazuaki |
| description | The changes of BCVA were 0.10 ± 0.37 in polypoidal CNV and 0.13 ± 0.18 in idiopathic PCV, with no significant difference between the 2 groups (P = .740). [...]in our study, there were no significant differences between polypoidal CNV and idiopathic PCV in both anti-vascular endothelial growth factor (VEGF) agents during the 1-year follow-up period. Because fellow eyes covered diseased eyes, some patients could not notice their symptoms and did not know exactly the onset of AMD. |
| doi_str_mv | 10.1016/j.ajo.2016.11.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1861140002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4307161601</sourcerecordid><originalsourceid>FETCH-proquest_journals_18611400023</originalsourceid><addsrcrecordid>eNpjYJA0NNAzNDA008_SS8zK1zMCMvUMDfUMDCyYGDgNLcwtdQ0tLA1ZGDgNDAyMdC2NLU04GLiKi7OAXDNzE3NOBtag1IKcSh4G1rTEnOJUXijNzaDs5hri7KFbUJRfWJpaXBKflV9alAeUije0MDM0NAEZZ0ycKgAEcSnR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1861140002</pqid></control><display><type>article</type><title>Reply</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Maruyama-Inoue, Maiko ; Yamane, Shin ; Sato, Shimpei ; Kadonosono, Kazuaki</creator><creatorcontrib>Maruyama-Inoue, Maiko ; Yamane, Shin ; Sato, Shimpei ; Kadonosono, Kazuaki</creatorcontrib><description>The changes of BCVA were 0.10 ± 0.37 in polypoidal CNV and 0.13 ± 0.18 in idiopathic PCV, with no significant difference between the 2 groups (P = .740). [...]in our study, there were no significant differences between polypoidal CNV and idiopathic PCV in both anti-vascular endothelial growth factor (VEGF) agents during the 1-year follow-up period. Because fellow eyes covered diseased eyes, some patients could not notice their symptoms and did not know exactly the onset of AMD.</description><identifier>ISSN: 0002-9394</identifier><identifier>EISSN: 1879-1891</identifier><identifier>DOI: 10.1016/j.ajo.2016.11.008</identifier><identifier>CODEN: AJOPAA</identifier><language>eng</language><publisher>Chicago: Elsevier Limited</publisher><subject>Macular degeneration ; Occult sciences ; Retina ; Vascular endothelial growth factor</subject><ispartof>American journal of ophthalmology, 2017-02, Vol.174, p.182</ispartof><rights>Copyright Elsevier Limited Feb 01, 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Maruyama-Inoue, Maiko</creatorcontrib><creatorcontrib>Yamane, Shin</creatorcontrib><creatorcontrib>Sato, Shimpei</creatorcontrib><creatorcontrib>Kadonosono, Kazuaki</creatorcontrib><title>Reply</title><title>American journal of ophthalmology</title><description>The changes of BCVA were 0.10 ± 0.37 in polypoidal CNV and 0.13 ± 0.18 in idiopathic PCV, with no significant difference between the 2 groups (P = .740). [...]in our study, there were no significant differences between polypoidal CNV and idiopathic PCV in both anti-vascular endothelial growth factor (VEGF) agents during the 1-year follow-up period. Because fellow eyes covered diseased eyes, some patients could not notice their symptoms and did not know exactly the onset of AMD.</description><subject>Macular degeneration</subject><subject>Occult sciences</subject><subject>Retina</subject><subject>Vascular endothelial growth factor</subject><issn>0002-9394</issn><issn>1879-1891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpjYJA0NNAzNDA008_SS8zK1zMCMvUMDfUMDCyYGDgNLcwtdQ0tLA1ZGDgNDAyMdC2NLU04GLiKi7OAXDNzE3NOBtag1IKcSh4G1rTEnOJUXijNzaDs5hri7KFbUJRfWJpaXBKflV9alAeUije0MDM0NAEZZ0ycKgAEcSnR</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Maruyama-Inoue, Maiko</creator><creator>Yamane, Shin</creator><creator>Sato, Shimpei</creator><creator>Kadonosono, Kazuaki</creator><general>Elsevier Limited</general><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20170201</creationdate><title>Reply</title><author>Maruyama-Inoue, Maiko ; Yamane, Shin ; Sato, Shimpei ; Kadonosono, Kazuaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_18611400023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Macular degeneration</topic><topic>Occult sciences</topic><topic>Retina</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maruyama-Inoue, Maiko</creatorcontrib><creatorcontrib>Yamane, Shin</creatorcontrib><creatorcontrib>Sato, Shimpei</creatorcontrib><creatorcontrib>Kadonosono, Kazuaki</creatorcontrib><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>American journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maruyama-Inoue, Maiko</au><au>Yamane, Shin</au><au>Sato, Shimpei</au><au>Kadonosono, Kazuaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reply</atitle><jtitle>American journal of ophthalmology</jtitle><date>2017-02-01</date><risdate>2017</risdate><volume>174</volume><spage>182</spage><pages>182-</pages><issn>0002-9394</issn><eissn>1879-1891</eissn><coden>AJOPAA</coden><abstract>The changes of BCVA were 0.10 ± 0.37 in polypoidal CNV and 0.13 ± 0.18 in idiopathic PCV, with no significant difference between the 2 groups (P = .740). [...]in our study, there were no significant differences between polypoidal CNV and idiopathic PCV in both anti-vascular endothelial growth factor (VEGF) agents during the 1-year follow-up period. Because fellow eyes covered diseased eyes, some patients could not notice their symptoms and did not know exactly the onset of AMD.</abstract><cop>Chicago</cop><pub>Elsevier Limited</pub><doi>10.1016/j.ajo.2016.11.008</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9394 |
| ispartof | American journal of ophthalmology, 2017-02, Vol.174, p.182 |
| issn | 0002-9394 1879-1891 |
| language | eng |
| recordid | cdi_proquest_journals_1861140002 |
| source | ScienceDirect Journals (5 years ago - present) |
| subjects | Macular degeneration Occult sciences Retina Vascular endothelial growth factor |
| title | Reply |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T12%3A29%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reply&rft.jtitle=American%20journal%20of%20ophthalmology&rft.au=Maruyama-Inoue,%20Maiko&rft.date=2017-02-01&rft.volume=174&rft.spage=182&rft.pages=182-&rft.issn=0002-9394&rft.eissn=1879-1891&rft.coden=AJOPAA&rft_id=info:doi/10.1016/j.ajo.2016.11.008&rft_dat=%3Cproquest%3E4307161601%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1861140002&rft_id=info:pmid/&rfr_iscdi=true |